for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

157.43USD

Change

5.50(+3.62%)

Volume

19,123,403

Today's Range

149.00

 - 

164.55

52 Week Range

17.91

 - 

178.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Moderna Looking At Studying A Third Covid-19 Booster Shot 6 To 12 Months After Second Vaccine Shot, But Not Sooner- Conf. Call

Jan 25 (Reuters) - Moderna Inc <MRNA.O>::Moderna CMO says currently looking at studying a third COVID-19 booster shot 6 to 12 months after second vaccine shot, but not sooner- conf. call.Moderna exec says expect the durability of protection from the primary series of its COVID-19 vaccine to be a year or longer- conf.call.Further company coverage: MRNA.O. (Reporting By Michael Erman). ((Michael.Erman@thomsonreuters.com;)).

Moderna Says Based On Available Evidence To Date, Vaccine Immunity Should Last At Least A Year- JPM Conf. Call

Jan 11 (Reuters) - Moderna Inc <MRNA.O>::CEO SAYS EXPECTS 2021 POTENTIAL REVENUES OF $11.7 BILLION IF PRODUCTS ARE DELIVERED IN THIS YEAR- JPM CONF. CALL.CEO SAYS EXPECTS TO DELIVER 600 MILLION DOSES OF ITS COVID-19 VACCINE IN 2021- JPM CONF. CALL.CEO SAYS IS VERY COMFORTABLE TO ACHIEVE UP TO 1 BILLION DOSES OF ITS COVID-19 VACCINE IN 2021- JPM CONF. CALL.EXECUTIVE SAYS MODERNA'S TECHNOLOGY IS VERY WELL SUITED TO RAPIDLY DEPLOY A VACCINE BASED ON THE NEW VARIANT- JPM CONF. CALL.SAYS BASED ON AVAILABLE EVIDENCE TO DATE, VACCINE IMMUNITY SHOULD LAST AT LEAST A YEAR- JPM CONF. CALL.Further company coverage: <MRNA.O>. ((Reuters.Briefs@thomsonreuters.com;)).

Moderna Says FY 2021 APA Product Revenue For Delivery Of COVID-19 Vaccine Is $11.7 Bln

Jan 11 (Reuters) - Moderna Inc <MRNA.O>::MODERNA PROVIDES BUSINESS UPDATE AND ANNOUNCES THREE NEW DEVELOPMENT PROGRAMS IN INFECTIOUS DISEASE VACCINES.MODERNA INC - MODERNA NOW HAS ONE COMMERCIAL MEDICINE AND 24 DEVELOPMENT PROGRAMS.MODERNA INC - MULTIPLE THERAPEUTIC PROGRAMS ANTICIPATED TO SEE CLINICAL PROOF OF CONCEPT DATA IN 2021.MODERNA INC - HIV VACCINE PROGRAM TO ACCELERATE HUMAN VALIDATION OF NOVEL VACCINATION STRATEGIES.MODERNA INC - ALSO ANNOUNCED AN EXPANSION OF ITS RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE PROGRAM INTO OLDER ADULTS.MODERNA INC - NIPAH VACCINE PROGRAM ESTABLISHED AGAINST A VIRUS OF PUBLIC HEALTH CONCERN.MODERNA INC - EXPECTS TO BEGIN PHASE 1 CLINICAL TRIALS FOR BOTH MRNA-1644 AND MRNA-1574 IN 2021.MODERNA INC - TO DATE, PRODUCT REVENUE ASSOCIATED WITH APAS FOR DELIVERY OF ITS COVID-19 VACCINE FOR FY 2021 IS $11.7 BILLION.MODERNA INC - IS IN ACTIVE DISCUSSIONS TO SIGN ADDITIONAL APAS FOR DELIVERIES IN 2021 AND 2022.MODERNA INC - ALSO MADE A PROPOSAL TO COVAX VIA A UNICEF TENDER TO SUPPLY LOW-AND-MID INCOME COUNTRIES.

UK to Clear Moderna Vaccine as Soon as Friday - Bloomberg

Jan 8 (Reuters) - :U.K. IS REVIEWING MODERNA'S COVID-19 VACCINE ON AN ACCELERATED TIMETABLE, POISED TO AUTHORIZE IT FOR EMERGENCY USE AS SOON AS FRIDAY - BLOOMBERG.

European Commission Authorizes COVID-19 Vaccine Moderna In Europe

Jan 6 (Reuters) - Moderna Inc <MRNA.O>::EUROPEAN COMMISSION AUTHORIZES COVID-19 VACCINE MODERNA IN EUROPE.MODERNA INC - EUROPEAN COMMISSION HAS SECURED 160 MILLION DOSES; FIRST DELIVERIES TO COUNTRIES WILL BEGIN NEXT WEEK.MODERNA INC - ADDITIONAL AUTHORIZATIONS ARE CURRENTLY UNDER REVIEW IN SINGAPORE, SWITZERLAND AND UNITED KINGDOM..

EMA Recommends Moderna's COVID-19 Vaccine For Authorisation In EU

Jan 6 (Reuters) - European Medicines Agency::EMA RECOMMENDS COVID-19 VACCINE MODERNA FOR AUTHORISATION IN EU.EMA SAYS COVID-19 VACCINE MODERNA IS GIVEN AS TWO INJECTIONS INTO ARM, 28 DAYS APART.EMA SAYS RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR COVID-19 VACCINE MODERNA IN PEOPLE FROM 18 YEARS OF AGE..EMA SAYS THE EUROPEAN COMMISSION WILL NOW FAST-TRACK DECISION-MAKING PROCESS TO GRANT A DECISION ON THE CONDITIONAL MARKETING AUTHORISATION FOR COVID-19 VACCINE MODERNA.EMA SAYS COMPANY THAT MARKETS COVID-19 VACCINE MODERNA WILL CONTINUE TO PROVIDE RESULTS FROM THE MAIN TRIAL, WHICH IS ONGOING, FOR 2 YEARS.

Scientists Are Studying If The Moderna Vaccine Supply Can Be Doubled By Cutting Doses In Half - NYT

Jan 5 (Reuters) - :SCIENTISTS ARE STUDYING IF THE MODERNA VACCINE SUPPLY CAN BE DOUBLED BY CUTTING DOSES IN HALF - NYT.

FDA Statement On Following The Authorized Dosing Schedules For COVID-19 Vaccines

Jan 4 (Reuters) - :FDA STATEMENT ON FOLLOWING THE AUTHORIZED DOSING SCHEDULES FOR COVID-19 VACCINES.FDA SAYS "TWO DIFFERENT MRNA VACCINES HAVE NOW SHOWN REMARKABLE EFFECTIVENESS OF ABOUT 95% IN PREVENTING COVID-19 INFECTION IN ADULTS".FDA - "SUGGESTING CHANGES TO THE FDA-AUTHORIZED DOSING OR SCHEDULES OF THESE VACCINES IS PREMATURE AND NOT ROOTED SOLIDLY IN THE AVAILABLE EVIDENCE".FDA - AVAILABLE DATA CONTINUE TO SUPPORT THE USE OF TWO SPECIFIED DOSES OF EACH AUTHORIZED VACCINE AT SPECIFIED INTERVALS.FDA-FOR PFIZER-BIONTECH VACCINE, INTERVAL IS 21 DAYS BETWEEN 1ST & 2ND DOSE; FOR MODERNA COVID-19 VACCINE, INTERVAL IS 28 DAYS BETWEEN 1ST & 2ND DOSE.FDA- "WHAT WE HAVE SEEN IS THAT THE DATA IN THE FIRMS’ SUBMISSIONS REGARDING THE FIRST DOSE IS COMMONLY BEING MISINTERPRETED".FDA- UNTIL VACCINE MAKERS HAVE DATA SUPPORTING CHANGE, WE CONTINUE TO STRONGLY RECOMMEND HEALTH CARE PROVIDERS FOLLOW FDA-AUTHORIZED DOSING SCHEDULE.

Moderna Provides Covid-19 Vaccine Supply Update

Jan 4 (Reuters) - Moderna Inc <MRNA.O>::MODERNA PROVIDES COVID-19 VACCINE SUPPLY UPDATE.MODERNA INC - CONTINUES TO INVEST AND HIRE IN ORDER TO DELIVER UP TO 1 BILLION DOSES IN 2021.MODERNA INC - RAISES LOWER END OF GLOBAL MANUFACTURING PLAN FOR 2021 FROM 500 MILLION DOSES PREVIOUSLY TO 600 MILLION DOSES.MODERNA INC - CONTINUES TO INVEST AND HIRE IN ORDER TO DELIVER UP TO 1 BILLION DOSES IN 2021.MODERNA INC - EXPECTS ABOUT 100 MILLION DOSES TO BE AVAILABLE IN UNITED STATES BY END OF Q1 OF 2021.MODERNA INC - REPORTED THAT APPROXIMATELY 18 MILLION DOSES HAVE BEEN SUPPLIED TO U.S. GOVERNMENT TO DATE.MODERNA - ADDITIONAL VACCINE DOSES HAVE BEEN SUPPLIED TO CANADIAN GOVERNMENT FOLLOWING AUTHORIZATION BY HEALTH CANADA'S INTERIM ORDER ON DEC 23, 2020.MODERNA INC - EXPECTS ABOUT 100 MILLION DOSES TO BE AVAILABLE IN UNITED STATES BY END OF Q1 OF 2021, WITH 200 MILLION DOSES TOTAL AVAILABLE BY END OF Q2.

Moderna Expects Its Covid-19 Vaccine To Be Protective Against Variants Of Coronavirus Recently Described In UK

Dec 23 (Reuters) - Moderna Inc <MRNA.O>::MODERNA INC - STATEMENT ON VARIANTS OF SARS-COV-2 VIRUS.MODERNA -RANGE OF POTENTIAL NEUTRALIZING ANTIBODIES PROVIDE CONFIDENCE COVID-19 VACCINE WILL BE EFFECTIVE AT INDUCING NEUTRALIZING ANTIBODIES AGAINST ANY STRAIN.MODERNA - TESTED SERA FROM ANIMALS, HUMANS VACCINATED WITH CO'S COVID-19 VACCINE AGAINST NUMBER OF PRIOR VARIANTS OF VIRUS THAT EMERGED SINCE OUTBREAK.MODERNA - EXPECTS VACCINE-INDUCED IMMUNITY CO'S COVID-19 VACCINE WOULD BE PROTECTIVE AGAINST VARIANTS OF SARS-COV-2 VIRUS RECENTLY DESCRIBED IN THE UK.MODERNA - WILL BE PERFORMING ADDITIONAL TESTS OF CO'S COVID-19 VACCINE IN COMING WEEKS TO CONFIRM EXPECTATION AGAINST VARIANTS OF VIRUS DESCRIBED IN UK.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up